Research on the expression of miR-186-5p in serum of patients with colon cancer#br#

doi:10.12092/j.issn.1009-2501.2020.10.003

Abstract

Abstract: AIM: To investigate the expression of miR-186-5p in colon cancer and the effect on colon cancer, and provide a new therapeutic target for the treatment and prognosis of colon cancer. METHODS: Serum from eligible patients were collected and divided into five groups (n=20) including the healthy group and clinical stages I, II, III and IV. The miRNAs in patients' serum were extracted by miRVana microRNA isolation kit. The differences of miR-186-5p expression in patients' serum of colon cancer at different stages were detected with real-time quantitative PCR. The full-length gene of miR-186-5p was cloned into pENTR/D-Topo vector to construct cell lines with high expression of miRNA. 5×103 cells were seeded in 96-well plates. The expression of mir-186-5p was decreased by using miR-186-5p inhibitor. The proliferation of cells was detected with cell proliferation ELISA kit after 24 hours of incubation with BrdU and absorbance was measured at 370 and 492 nm. The effect of miR-186-5p on the sensitivity of colon cancer cell lines to chemotherapeutic drugs was detected by MTT assay. RESULTS: The expression of miR-186-5p was down-regulated in the serum of patients with colon cancer compared to normal group. Expression of miR-186-5p in serum of patients with stage I, II, III and IV was significantly decreased (P<0.01) compared with the normal group. Colon cells were transfected with a plasmid integrating the miR-186-5p gene, and miR-186-5p was highly expressed in the HCT116 and SW480 cell lines (P<0.01). The expression of mir-186-5p was decreased by mir-186-5p inhibitor (hsa-miR-186-5p inhibitor) in HCT116 and SW480 cells. The proliferation rate of HCT116 and SW480 cells with high expression of miR-186-5p was lower than control group (P<0.01). After treating with mir-186-5p inhibitor, the cell proliferation rate was higher than that of the control group (P<0.01). After treatment with different concentrations cisplatin for 24 hours, the mortality of HCT116 and SW480 cells with high expression of mir-186-5p was higher than that of the control group (P<0.01). The mortality of the cells with low expression of mir-186-5p was lower than that of the control group (P<0.01). The protein level of PLK1 was decreased after transfecting with miR-186-5p plasmid and increased after stimulating with miR-186-5p inhibitor in HCT116 and SW480 cells. CONCLUSION: The expression of miR-186-5p is decreased in colon cancer patients. Overexpression of miR-186-5p can inhibit the proliferation of colon cancer cells and reduce the drug resistance of colon cancer cells; inhibition of miR-186-5p expression can increase the proliferation and drug resistance of colon cancer cells.

Key words: colon cancer, miR-186-5p, plasmid, cell proliferation, cisplatin

CLC Number:

CHENG Jianping, LI Zhen, ZHAO Xiaolin, YANG Mengyuan, JI Xiwei, YU Jiufei. Research on the expression of miR-186-5p in serum of patients with colon cancer#br#[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1097-1104.

References 21

[1]	Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients [J]. J Clin Oncol, 2015, 33(16):1787-96.
[2]	Xie XN, Yu J, Zhang LH, et al. Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population [J]. Funct Integr Genomics, 2019, 19(2):227-236.
[3]	Saugstad JA. MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration [J]. J Cereb Blood Flow Metab, 2010, 30(9):1564-76.
[4]	Madathil SK, Nelson PT, Saatman KE, Wilfred BR. MicroRNAs in CNS injury: potential roles and therapeutic implications [J]. Bioessays, 2011, 33(1):21-6.
[5]	Fiedler J, Thum T. MicroRNAs looping around angiogenesis [J]. Arterioscler Thromb Vasc Biol, 2011, 31(11):2367-8.
[6]	Zendjabil M, Favard S, Tse C, et al. [The microRNAs as biomarkers: What prospects?] [J]. C R Biol, 2017, 340(2):114-131.
[7]	Tordonato C, Di Fiore PP, Nicassio F. The role of non-coding RNAs in the regulation of stem cells and progenitors in the normal mammary gland and in breast tumors [J]. Front Genet, 2015, 6(72.
[8]	Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee [J]. J Clin Oncol, 2005, 23(31):7951-7.
[9]	Calin GA, Croce CM. MicroRNA signatures in human cancers [J]. Nat Rev Cancer, 2006, 6(11):857-66.
[10]	Jia W, Wu Y, Zhang Q, et al. Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer [J]. Oncol Lett, 2013, 6(1):261-267.
[11]	Myatt SS, Wang J, Monteiro LJ, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer [J]. Cancer Res, 2010, 70(1):367-77.
[12]	Zhou L, Qi X, Potashkin JA, et al. MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3'-untranslated region of the gene that decrease steady-state levels of the transcript [J]. J Biol Chem, 2008, 283(42):28274-86.
[13]	Yang J, Yuan D, Li J, et al. miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition [J]. Tumour Biol, 2016, 37(4):4331-41.
[14]	Wang H, Shen Q, Zhang X, et al. The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p [J]. Cell Physiol Biochem, 2017, 41(6):2221-2229.
[15]	Zhou T, Lin W, Zhu Q, et al. The role of PEG3 in the occurrence and prognosis of colon cancer [J]. Onco Targets Ther, 2019, 12(6001-6012.
[16]	Gelman IH. Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis [J]. Genes Cancer, 2010, 1(11):1147-56.
[17]	Ries J, Vairaktaris E, Agaimy A, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood [J]. Oncol Rep, 2014, 31(3):1429-36.
[18]	Yao K, He L, Gan Y, et al. MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1 [J]. Diagn Pathol, 2015, 10(146.
[19]	Liu Z, Zhang G, Yu W, et al. miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1 [J]. Biochem Biophys Res Commun, 2016, 469(3):692-7.
[20]	He H, Kim J. Regulation and function of the peg3 imprinted domain [J]. Genomics Inform, 2014, 12(3):105-13.
[21]	Murphy SK, Wylie AA, Jirtle RL. Imprinting of PEG3, the human homologue of a mouse gene involved in nurturing behavior [J]. Genomics, 2001, 71(1):110-7.